CRH predicts annual earnings of up to €6.6bn as Q2 profits climb 9%
CRH is now the largest building materials producer in the US and CEO Jim Mintern made the comments after the industrial giant reported a better than expected 9% rise in second quarter core profit and forecast full-year earnings of $7.5bn (€6.4bn) to $7.7bn (€6.6bn), versus a prior range of $7.3bn to $7.7bn.
The Irish-based, US-listed firm, which makes about 75% of its profit in North America, agreed to acquire US SCM supplier Eco Material Technologies for $2.1bn (€1.8bn) last month to meet growing demand for the alternative ash-based products.
"In particular what attracted us (to the deal) is that when you look out in the US, we estimate that the SCM market is going to double between now and 2050," Mintern said.
"This deal puts us right up there in terms of size and leadership levels in the US (and) gives us a very good growth platform."
The acquisition will boost CRH's capacity in the 135m metric ton US SCM market to about 25m tons, he added. CRH is the third largest cement manufacturer in both North America and Europe.
CRH's second quarter adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of $2.5b (€2.13bn) were ahead of the $2.4bn expected by an average of seven analysts polled by LSEG SmartEstimate.
Mintern said the increase in the lower end of its full year guidance range was based on trading in the seasonally important month of July and a year-on-year increase in the volume and margins of contracted work across all major US product lines.
Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Irish Sun
2 hours ago
- The Irish Sun
Marks & Spencer issue update to Irish customers after major cyber attack & reveal big discount for shoppers
The special code will be available for one week SHOP ALERT Marks & Spencer issue update to Irish customers after major cyber attack & reveal big discount for shoppers MARKS & Spencer has issued a big update to Irish customers 15 weeks after the company was targeted in a major cyber attack. The supermarket chain was forced to suspend its online shopping after the incident in April. 1 Marks & Spencer was attacked on April 19 Credit: Getty Managing Director, Fashion, Home & Beauty, John Lyttle said: "To our valued Irish customers, thank you for your patience as we continue to work hard behind the scenes to restore our services to you. "We plan to have them all fully back up and running soon. "To thank you for your support, customers can enjoy 20% off when shopping in-store on fashion and home. "This can be accessed on our M&S app from Thursday 14 August to Wednesday 20 August. "Our stores across Ireland remain open and our colleagues are ready to welcome you." Back in April, the retailer's CEO Stuart Machin had already reached out to customers after the incident to explain what was going on. He said: "I'm writing to let you know that over the last few days M&S has been managing a cyber incident. 'To protect you and the business, it was necessary to temporarily make some small changes to our store operations, and I am sincerely sorry if you experienced any inconvenience." Cybersecurity expert Professor Oli Buckley said these kinds of attacks often have lingering effects. He said: 'We often see a cyber attack as a brief flash, it comes out of nowhere. "We learn that some data has disappeared and then everything is up and running again. 'In reality, the impacts usually linger for far longer, but that isn't usually of much interest as the exciting bit has already happened, and it often happens behind the scenes. 'Marks & Spencer and the Co-op are facing that kind of incident, it's the equivalent of a burst pipe, but it isn't just one room that's flooded, instead we're seeing the floorboards starting to warp and the plaster get a bit soggy." CAUSES CHAIN REACTION Buckley also said these businesses have intricate networks where one problem can cause a chain reaction across deliveries, services and stock. And it's now confirmed that personal info like names and contact details was exposed - even though no payment data was taken. Buckley added: 'We now know that personal customer data, names, addresses, contact details, has been compromised. 'While no payment information was compromised, breaches like this feel deeply personal. "It's one thing to lose access to your online shop, quite another to wonder who now has your email address or order history.'
Irish Times
3 hours ago
- Irish Times
From pharma to food, the known unknowns of Trump's EU tariffs deal
The US/ EU tariff deal was meant to bring certainty for exporters. But almost three weeks later there is a lot that we don't know – and more that remains uncertain. A joint statement signed off by both sides had been expected shortly after the big summit in Scotland at the end of July , clarifying key parts of the deal and how it would be implemented. But this week, a European Commission spokesperson said, in best bureacrateese, that while further contacts with the US were expected on this, 'I don't believe at this stage we can put a timeline on these engagements.' 1. What is covered by the new tariffs? The deal had been hailed as bringing 'certainty' to Irish exporters. And it has done so, but only up to a point. A blanket 15 per cent tariff now applies on most categories or exports from Ireland to the US. READ MORE As ever with trade, there are tweaks. Some goods which had been subject to previous higher tariff charges (under the most favoured nation or MFN system) will still pay these. For Ireland, the main product affected here is butter – with Kerrygold now the second biggest seller on the US market. Before Trump came to office it had been levied at a rate based on weight – rather than the more usual percentage calculation. However, this worked out at somewhere over 16 per cent in practice. So this slightly higher rate will remain. Other sectors face tariffs for the first time, or higher charges. For example, the large medical products sector had previously been largely exempted, but is now being levied at 15 per cent. So are parts of the food sector and spirits. 2. What is not covered? US customs has published a list of goods that are excluded from the 15 per cent tariff and Carol Lynch, customs partner at BDO, says this is a good place for SMEs unsure if they are covered to check. A key point for Ireland is that pharma products, by far the State's biggest in value terms, are not currently subject to the 15 per cent tariff. This may change, as the Trump administration is undertaking a study of pharma supply into the US market and the national security issues that apply – the so-called section 232 investigation which refers back to a 1960s act of congress. This is the backdrop to Trump's talk of 150 per cent or 250 per cent tariffs on pharma in 18 months or two years' time, applying to companies that do not play ball and return production to the US market. The EU believes the US has signed up to a 15 per cent cap on pharma – and semiconductor – tariffs under the deal, but Trump's subsequent statements suggest otherwise. This is why the absence of a joint agreed statement between the EU and US is important. 3. What might change? Another frustration for the EU is that the outline agreement suggested that more areas would be excluded from the 15 per cent tariff net but, beyond aircraft and aircraft parts, none of these has yet been spelt out. These 'carveouts' were due to cover some areas of food of potential interest to Ireland, some generic drugs and chemicals and perhaps medical devices, a sector which typically has lower margins and fixed price contracts with US buyers. The EU had also been pushing for a 'zero for zero' tariff deal on wines and spirits, though the indications were the US was unlikely to concede this. So bar the list published by US Customs, we are no wiser on what other sectors may, in time, get a pass. 4. What can companies do? The practical steps, according to Lynch of BDO, are, first, to check whether goods were in transit before August 7th, in which case the old 10 per cent rate would apply rather than the new 15 per cent. Companies need to know the tariff codes being used by those importing their products and whether any of the exclusions they know about so far apply. And, she says, they need to examine whether they have any flexibility under the rules in terms of the value of goods declared for customs purposes. This is a complex area with detailed pricing rules applying but, particularly in high value sectors like pharma, companies may have options to readjust supply changes or pricing policies to cut their tariff bills. 5. Where next on pharma? The Trump administration has been promising the results of its section 232 investigation shortly, expected by way of a big report. Alongside this, Trump's team have been negotiating on prices with the big US pharma companies, demanding that they charge the same prices in the US as other countries. A 2022 study showed that US prices were, on average, three times higher than the OECD average. This – in Trump's view- means prices should fall in the US and rise in other countries, thus giving the US consumer a better deal while giving companies ongoing revenue to fund research. It is unclear what the outcome of this will be but the two areas are linked. Imposing tariffs on imports risks increasing prices on the US market, the opposite of the goal of the price negotiations. The US president is threatening tariffs which would gradually increase over time as a way of getting big pharma to relocate more production to the US of key drugs and ingredients. So will we see 15 per cent pharma tariffs when the result of the Section 232 probes are out? Or will the US president hold off for now while holding out the threat of tariffs if big pharma does not fall into line on prices and investment? 6. Ireland's pharma exposure: In a post on the pharma issue on LinkedIn, Ben McConkey, an Irish MSc student at the London School of Economics, underlines the extent of Ireland's 'pharma' exposure by pointing out that the US imported over $50 billion worth of Irish pharmaceutical products in 2004, making it the single largest category of goods imported from any EU country by a margin of $15 billion and representing 8.3 per cent of all US imports from the EU. While the noise around the trade talks was about German cars, Irish pharma exports have a higher value, though this is of course hugely inflated by the pricing practices of the firms involved, which have a financial incentive to declare as much profit as possible in low tax Ireland. McConkey also makes the interesting point that the bulk of Irish pharma and organic chemicals go to republican states such as Indiana – home of Eli Lilly – as well as Puerto Rico, North Carolina and Illinois. Many are not finished drugs but are high value ingredients in drugs then sold across the US. As tariffs will have an economic impact on these companies – and on US consumers – it remains to be seen what the president decides. But the stakes for Ireland in the Section 232 process are huge as it could influence both future manufacturing investment and the transfer pricing structures the companies employ which led to huge profits being declared in Ireland and a lot of corporate tax being paid here. 7. The uncertainty may just roll on: The EU's belief was that a joint statement would be agreed with the US on the basis of the political agreement between Trump and European Commission president Ursula von der Leyen in Scotland. This would then be followed by further detailed negotiations. It is unclear if the absence of even a basic, joint written understanding is just a result of August holidays or whether it is a sign of the way the US president tends to operate – in headlines and in a way which leaves him with maximum flexibility to change tack. The president and his team have been continuing to push the boat out in terms of tariffs and pressure on US businesses to bend to their will. There is a fair chance that the uncertainty will roll on – and on. And this in itself will have a cost on businesses, even if the 15 per cent deal will have left many feeling they have some more solid ground on which to plan. And, it must be remembered that the US president's right to impose the 15 per cent tariffs at all is being challenged in the courts – a process likely to go right to the US supreme court for an ultimate decision.
RTÉ News
5 hours ago
- RTÉ News
Euro zone industry shrinks more than feared in June but GDP holds up
Euro zone industrial output dipped more than expected in June even as overall economic growth held up in the second quarter, challenging views that the 20 nation currency union remains resilient to the fallout from a global trade war. Industrial output fell 1.3% on the month in June, driven by a big dip in Germany and weak consumer goods production, underperforming expectations for a 1.0% fall, data from Eurostat showed today. Adding to the negative surprise, Eurostat also revised its output growth estimate for May to 1.1% from 1.7%, suggesting that the underlying trend is weaker than thought. Meanwhile GDP grew by 0.1% on the quarter, in line with a preliminary estimate, and employment rose just 0.1% on the quarter, in line with expectations in a Reuters poll, but below the 0.2% in the previous three months. A recent string of relatively upbeat indicators from purchasing managers (PMI) data to the European Commission's sentiment reading have fuelled a narrative that consumption is keeping the bloc resilient to trade tensions, but more recent numbers, like industrial orders and a key sentiment reading from Germany, have challenged this view. Still, investors continue to bet on a modest upturn on the premise that a recent EU trade deal with the US provides much needed certainty and Germany's plans to sharply boost budget spending will support growth. This is why financial investors think the ECB may be done cutting interest rates and policymakers will sit out a temporary dip in inflation below the 2% target, as price pressures over the medium term are already building up. Growth is unlikely to take off, however, and the euro zone is facing modest expansion of only around 1% a year in the coming years, trailing other major economies, given structural inefficiencies. Compared to a year earlier, second quarter economic growth was 1.4%, a figure that is boosted by a one-off demand surge before US tariffs took effect. This figure is now seen slowing steadily before picking up in 2026. The monthly industrial fall was driven by a 2.3% drop in Germany and an 11.3% fall in Ireland, a figure that is unlikely to concern many, since Irish data is exceptionally volatile due to activity among big multinational companies, mostly in pharmaceuticals, based here for tax purposes. Industry figures showed that besides energy production, every sector took a dip last month, led by a 4.7% fall in non-durable consumer goods and a 2.2% fall in capital goods production.
